In the context of the “Pisan Neurological Days 2023,” held in Pisa from Nov. 16 to 18 and promoted by Professor Gabriele Siciliano (Director of the Neurological Clinic of the Azienda Ospedaliero-Universitaria Pisana), the Meeting “Mitochondrial Medicine – The Genomit Initiative” was held, organized by Professor Michelangelo Mancuso, a neurologist and professor at the University of Pisa.
It was a major event attended by international experts in the field of Mitochondrial Diseases from Italy, Germany, the United States, the United Kingdom, China and Japan, who are actively engaged in the diagnosis, research and treatment of mitochondrial diseases.
The prestigious Aula Magna of the Scuola Superiore Sant’Anna (Pisa) was the setting for this meeting, which took place on November 17 and 18. Aliveda actively supported this event as an official sponsor. The company, represented by Drs. Lucia Chico and Linda Balestrini, Aliveda medical direction, demonstrated a tangible commitment to the advancement of research in the medical field, particularly in mitochondrial genetic diseases. Also present were Aliveda CEO Maico Polzella, Dr. Alessandro Toscano, commercial director, and Dr. Eleonora Nannetti, Aliveda ISF.
The presence of Aliveda’s medical leadership confirmed the company’s proactive role in promoting awareness and scientific research, thus contributing to the many challenges in understanding these rare diseases, which to date have been orphaned by effective treatments.
The Genomit Initiative proved to be a time for sharing knowledge, experiences and advances in understanding mitochondrial diseases. Aliveda, through its support, was able to consolidate collaboration with prestigious international research centers to address the complex challenge of managing and treating mitochondrial diseases.
We are ready for a nova challenge, stay tuned